Physician profile
Kevin Michael Fussell
NPI 1164404901
$787,605.69
in general payments reported to CMS, 2019-2025
44 companies · $239K in 2025
The $239K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $29K · 2021: $69K · 2022: $65K · 2023: $148K · 2024: $211K · 2025: $239K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $505K · Travel and Lodging: $48K · Consulting Fee: $25K · Food and Beverage: $20K · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $504,590.12 |
| Travel and Lodging | $48,460.84 |
| Consulting Fee | $24,705.00 |
| Food and Beverage | $20,383.22 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $554,246.64 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Genzyme Corporation | $123,820.22 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $101,835.36 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,239.38 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $1,205.71 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $704.25 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Grifols USA, LLC | $510.15 | 2019-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $377.55 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Philips North America LLC | $354.90 | 2019-2024 | (O58) Sleep Respiratory Care Und |
| Sunovion Pharmaceuticals INC. | $350.21 | 2019-2020 | |
| Ethicon INC. | $330.50 | 2019-2020 | |
| Pfizer INC. | $293.17 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $273.60 | 2019-2023 | Xarelto |
| Electromed, INC. | $254.60 | 2019-2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $148.71 | 2019-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Fussell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.